ADMS INVESTOR ALERT: ROSEN, A TOP LAW FIRM, Reminds Adamas Pharmaceuticals, Inc. Investors of Important February 10th Deadline in Securities Class Action – ADMSHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)ADMS INVESTOR ALERT: ROSEN, A TOP LAW FIRM, Reminds Adamas Pharmaceuticals, Inc. Investors of Important February 10th Deadline in Securities Class Action – ADMSGlobeNewswireJanuary 4, 2020ReblogShareTweetShareNEW YORK, Jan. 04, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Adamas Pharmaceuticals, Inc. (ADMS) between August 8, 2017 and September 30, 2019, inclusive (the “Class Period”) of the important February 10, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Adamas investors under the federal securities laws.To join the Adamas class action, go to http://www.rosenlegal.com/cases-register-1584.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) health insurers were excluding GOCOVRI from their prescription formularies or requiring patients to use "step therapy" - i.e., making patients try immediate-release amantadine prior to covering GOCOVRI; (2) the rapid increase in physicians prescribing GOCOVRI during the Class Period was not due to its efficacy; and (3) as a result of the foregoing, the Company's financial statements about Adamas's business, operations, and prospects were materially false and misleading at all relevant times.A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 10, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1584.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or cases@rosenlegal.com.Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney advertising. Prior results do not guarantee a similar outcome.Contact Information:      Laurence Rosen, Esq.       Phillip Kim, Esq.       The Rosen Law Firm, P.A.       275 Madison Avenue, 40th Floor       New York, NY 10016       Tel: (212) 686-1060       Toll Free: (866) 767-3653       Fax: (212) 202-3827       lrosen@rosenlegal.com       pkim@rosenlegal.com       cases@rosenlegal.com       www.rosenlegal.comReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextSteven Seagal to Pay SEC $314,000 for Failing to Disclose Payments Earned for Promotional WorkPeopleScotland Is Making Pads & Tampons Free For EveryoneRefinery29Steven Seagal Isn’t Above the Securities LawThe Wall Street JournalWabtec to pay $37 million in lawsuit settlementAmerican City Business JournalsWho Is Peter Nygard, The Canadian Millionaire Accused Of Raping 10 Girls & WomenRefinery 29 UKRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoMost face masks won’t protect you from the coronavirusYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoSEC sues 2 former South Carolina utility execs, alleging fraud at nuclear projectMarketWatchBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance Video